Skip to main content
Premium Trial:

Request an Annual Quote

Myriad, Genetic Technologies Ink Cross-Licensing Pact

NEW YORK, Oct. 28 - Myriad Genetics and Genetic Technologies Limited will cross-license a number of their technologies.


Under the terms of the deal, Myriad will pay GTL $1 million up front plus annual fees for a "broad, non-exclusive" license to its non-coding DNA-analysis and -mapping patents for human diagnostics and therapeutics.


GTL, meantime, will pay "various" undisclosed option fees and annual royalties to market Myriad's diagnostics in Australia and New Zealand.


Click here for more information.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.